

eScholarship

Title

Facial nerve preservation after vestibular schwannoma Gamma Knife radiosurgery

Permalink

<https://escholarship.org/uc/item/9s58z4g0>

Journal

Journal of Neuro-Oncology, 93(1)

ISSN

1573-7373

Authors

Yang, Isaac
Sughrue, Michael E.
Han, Seunggu J.
et al.

Publication Date

2009-05-01

DOI

10.1007/s11060-009-9842-3

Peer reviewed

Facial nerve preservation after vestibular schwannoma Gamma Knife radiosurgery

Isaac Yang · Michael E. Sughrue · Seunggu J. Han ·
Shanna Fang · Derick Aranda · Steven W. Cheung ·
Lawrence H. Pitts · Andrew T. Parsa

Received: 10 December 2008 / Accepted: 23 February 2009
© The Author(s) 2009. This article is published with open access at Springerlink.com

Abstract *Objective* Facial nerve preservation is a critical measure of clinical outcome after vestibular schwannoma treatment. Gamma Knife radiosurgery has evolved into a practical treatment modality for vestibular schwannoma patients, with several reported series from a variety of centers. In this study, we report the results of an objective analysis of reported facial nerve outcomes after the treatment of vestibular schwannomas with Gamma Knife radiosurgery. *Materials and methods* A Boolean Pub Med search of the English language literature revealed a total of 23 published studies reporting assessable and quantifiable outcome data regarding facial nerve function in 2,204 patients who were treated with Gamma Knife radiosurgery for vestibular schwannoma. Inclusion criteria for articles were: (1) Facial nerve preservation rates were reported specifically for vestibular schwannoma, (2) Facial nerve functional outcome was reported using the House–Brackmann classification (HBC) for facial nerve function, (3) Tumor size was documented, and (4) Gamma Knife radiosurgery was the only radiosurgical modality used in the report. The data were then aggregated and analyzed based on radiation doses delivered, tumor volume, and patient age. *Results* An overall facial nerve preservation rate of 96.2% was found after Gamma Knife radiosurgery for vestibular schwannoma in our

analysis. Patients receiving less than or equal to 13 Gy of radiation at the marginal dose had a better facial nerve preservation rate than those who received higher doses (≤ 13 Gy = 98.5% vs. >13 Gy = 94.7%, $P < 0.0001$). Patients with a tumor volume less than or equal to 1.5 cm^3 also had a greater facial nerve preservation rate than patients with tumors greater than 1.5 cm^3 ($\leq 1.5\text{ cm}^3$ 99.5% vs. $>1.5\text{ cm}^3$ 95.5%, $P < 0.0001$). Superior facial nerve preservation was also noted in patients younger than or equal to 60 years of age (96.8 vs. 89.4%, $P < 0.0001$). The average reported follow up duration in this systematic review was 54.1 ± 31.3 months. *Conclusion* Our analysis of case series data aggregated from multiple centers suggests that a facial nerve preservation rate of 96.2% can be expected after Gamma knife radiosurgery for vestibular schwannoma. Younger patients with smaller tumors less than 1.5 cm^3 and treated with lower doses of radiation less than 13 Gy will likely have better facial nerve preservation rates after Gamma Knife radiosurgery for vestibular schwannoma.

Keywords Stereotactic radiosurgery · Vestibular schwannoma · Facial nerve preservation · Gamma knife · Acoustic neuroma

Introduction

Gamma Knife radiosurgery (GKRS) has evolved into a practical alternative treatment to open microsurgical resection of vestibular schwannoma (VS) [1–30]. GKRS as a treatment modality for VS typically does not require inpatient hospitalization, however acute and chronic complications can occur [31–33]. In particular, radiation toxicity of neuro-anatomic structures adjacent to the tumor may develop and manifest as impaired function of the

I. Yang · M. E. Sughrue · S. J. Han · S. Fang · D. Aranda ·
L. H. Pitts · A. T. Parsa (✉)
Department of Neurological Surgery, University of California at
San Francisco, 505 Parnassus Ave, San Francisco, CA 94143,
USA
e-mail: ParsaA@Neurosurg.UCSF.Edu

S. W. Cheung
Department of Otolaryngology—Head and Neck Surgery,
University of California at San Francisco, San Francisco, CA,
USA

facial nerve, hearing loss, or loss of equilibrium and balance. [14, 16, 17, 23, 27, 30, 34–41]. Hydrocephalus, cerebral edema, and other cranial neuropathies have also been documented after GKRS, and in some reported cases required shunting as a treatment for hydrocephalus [4, 23, 37, 42–49].

Despite the available data on facial nerve outcome in VS patients treated with GKRS, there is no consensus as to what reported clinical parameters relate to facial nerve function. Most reported studies to date have been small to modest in size, frequently from a single institution, and lacking the statistical power and freedom from potential practitioner bias to draw concrete conclusions. Our review of the literature revealed widely varying results with reported facial nerve preservation between 55 and 100% after GKRS for VS (Table 1). Due to these factors and the multitude of methods to assess facial nerve preservation in the reported literature, facial nerve preservation after GKRS has not yet been fully characterized.

Several potential factors affecting facial nerve preservation after GKRS have been suggested, including the dose of radiation delivered, tumor volume, and patient age. In this study, we performed an extensive review of the English Language literature to objectively analyze and methodically evaluate facial nerve outcomes of patients with VS treated with GKRS. The primary aims were to provide an objective summary of the published literature on facial nerve preservation and to evaluate specific prognostic factors that may influence facial nerve preservation after GKRS for VS.

Methodology

Article selection

Articles were identified via Boolean PubMed searches using key words “Gamma knife,” “radiosurgery,” “acoustic neuroma,” “facial nerve,” “vestibular schwannoma,” and “facial nerve preservation,” alone and in combination. This query identified 23 papers describing over 2,204 patients from which all quantifiable and assessable data regarding patients treated with radiosurgery were analyzed. Articles published up to and including the year 2007 were included in this analysis. Inclusion criteria for articles were: (1) Facial nerve preservation rates were reported specifically for VS before and after GKRS, (2) Facial nerve outcome was reported using the House–Brackmann classification (HBC) for facial nerve function [5, 50–54], (3) Tumor size was documented, and (4) GKRS was the only radiation modality used to treat the tumor. The data were then aggregated and analyzed based on radiosurgery dose delivered, size of the tumor, and patient age.

Data extraction

Data from individual and aggregated cases were extracted from each paper. Cases with pre-operative facial dysfunction (HBC 3 or higher) were excluded. All recent cases of open microsurgery and radiotherapy other than GKRS were also excluded. “Facial nerve preservation” was defined as having a grade I or II HBC at the last reported follow-up visit. Overall average for facial preservation, patient age, and radiation dose were weighted accordingly to their sample size, so that larger and smaller series had an appropriate impact on the overall data. Data were analyzed as a whole and stratified into three groups. (1) Radiosurgery marginal dose ≤ 13 versus >13 Gy, (2) Tumor size ≤ 1.5 versus >1.5 cm³, and (3) Age ≤ 60 versus >60 years old.

Statistical analysis

The raw data were tabulated using Microsoft Excel (Microsoft Corp., Seattle, WA). All results were analyzed using a Fisher’s exact test or a *t*-test when appropriate for statistical evaluation of the data. For these statistical investigations, tests for significance were two sided, with a (two tailed) *P*-value threshold of 0.05 considered statistically significant. Unless otherwise stated, all continuous values presented were mean \pm standard deviation or standard error of measurement when appropriate.

Results

Results of comprehensive analysis

A total of 23 articles involving 2,204 patients with 1,908 patients meeting our inclusion criteria, were evaluated [1, 2, 11–13, 16, 17, 26, 41, 43, 44, 55–77] (Table 1). The overall facial nerve functional preservation rate in patients with VS treated with GKRS reported in the included studies was 96.2%. The mean of the reported average age of the patients in this analysis was 55.3 years (± 10.8 ; SEM ± 2.3) with an average of reported length of follow up duration of 54.1 months (± 31.4 months). Median length of follow up time in this analysis was 43.0 months. In this systematic analysis, the average of the published radiation doses used to treat these patients was 13.1 ± 2 Gy (SEM ± 0.4).

The effect of radiation dose on facial nerve preservation

A total of 1,038 reported patients were treated using an average marginal dose of ≤ 13 Gy, and 801 patients treated with an average marginal dose of >13 Gy. In this comparison, the group treated with lower dose radiosurgery (less than or equal to 13 Gy) had superior facial nerve preservation

Table 1 Data summary from papers listed by Pub Med ID and institution

PubMed ID		Total sample	CN VII intact	Avg age	Avg dose (Gy)	Avg tumor volume (cm ³)	Tumor ctrl rate (%)	Avg follow up (mo.)	CN VII preservation (%)
17379451	University of Pittsburgh	216	215	56.5	13.0	1.300	98.30	68.4	100.0
16741754	Ludwig Maximilians University	123	121	59	13.0	1.600	96.70	98.4	100.0
16094154	Komaki City Hospital	317	291	54	13.2	5.600	92.00	93.6	96.4
15854240	Haukeland University Hospital, Norway	103	102	59.7	12.2		89.20	70.8	94.8
15662791	Inst of Neural Org, Japan	18	9	–	–	15.200	93.33	72.0	100.0
15662787	Taipei Veterans Gen Hosp and Natl Yang Ming University	195	135	51	13.0	4.100	95.00	36.0	100.0
15354007	Medical College of Wisconsin	29	25	–	13.5		96.55	–	100.0
15337560	University of Pittsburgh	313	313	56	13.0	1.100	98.60	24.0	100.0
14617712	Royal Hallamshire Hospital, UK	232	179	56	14.6	3.350	92.00	35.0	99.1
14609174	Gunma Univ Sch of Med, Japan	1	1	63	12.0	0.520	0.00	27.0	0.0
14571654	Hospital Academique Erasme, Belgium	48	42	54.8	12.3	1.440	97.92	12.0	97.9
14519213	University of Pittsburgh	157	124	60	16.7	–	96.90	109.2	95.0
12520350	Addenbrooke’s Hospital, England	5	5	29	–	–	0.00	–	80.0
12459364	Baylor memorial Hermann Hospital	72	58	61.6	14.5		91.00	48.0	97.4
12379008	Karl-Franzens University, Graz, Austria	60	52	58	13.0	3.400	96.00	76.0	85.0
11483338	Thomas Jefferson Univ Hosp, PA	69	57	61	12.0	2.920	98.00	119.0	98.0
11143268	University of Tokyo	1	1	25	14.0	0.180	100.00	60.0	100.0
10821551	Northwestern Hospital	9	9	39	19.6		74.00	–	55.6
10030254	Mayo Clinic and Mayo Foundation [reduced protocol]	40	33	65	16.0	3.700	97.44	27.6	92.0
10030254	Mayo Clinic and Mayo Foundation [standard protocol]	42	35	63	–	3.000	97.44	27.6	62.0
9833820	Mayo Clinic/University of Pittsburgh	76	35	58	15.0	2.800	94.00	43.0	83.0
9392535	University of Tokyo	46	46	54	16.8	–	96.00	39.0	80.0
8588625	House Ear Clinic and House Ear Institute	1	1	39	–	–	0.00	24.0	100.0
7826279	University of Pittsburgh	31	19	55	–	0.600	90.00	26.0	95.0
Totals and Avg		2,204	1,908	55.3	13.1	3.2	82.5	54.1	96.2




Fig. 1 Facial nerve preservation analyzed by radiation dose of radiosurgery (*P* value indicated)

rates [≤ 13 Gy = 98.5% vs. > 13 Gy = 94.7%, $P < 0.0001$ (Fig. 1)]. Improved facial nerve preservation with low dose Gamma Knife radiosurgery suggests that radiation dose is a significant prognostic factor for facial nerve preservation with Gamma Knife radiosurgery. Patients with improved facial nerve preservation with low dose GKRS maintained good tumor control rates of 96.7%.

The effect of volume on facial nerve preservation

A total of 591 reported patients in our analysis had an average tumor volume of 1.5 cm³ or less, and 947 patients




Fig. 2 Facial nerve preservation analyzed by tumor volume stratified by tumors larger and smaller than 1.5 cm³ (*P* value indicated)

had an average tumor volume of >1.5 cm³. The patients with the smaller tumors (measuring 1.5 cm³ or less) had superior facial nerve preservation rates than those with larger tumors [≤ 1.5 cm³ 99.5% vs. >1.5 cm³ 95.5%, $P < 0.0001$ (Fig. 2)]. Smaller tumors were significantly associated with better facial nerve preservation after treatment with GKRS. The mean of the reported average radiation dose for smaller tumors was 12.9 ± 0.8 Gy which was less than the 13.7 ± 1.3 Gy that larger (>1.5 cm³) tumors received on average ($P < 0.0001$).

The effect of age on facial nerve preservation

A total of 1,690 patients were reported to have an average age equal to or younger than 60 years, and 184 patients were reported to be older than 60 years on average at the time of Gamma Knife radiosurgery. Facial nerve preservation was noted to be worse in patients older than 60 years of age [≤ 60 years = 96.8% vs. >60 years = 89.4%, $P < 0.0001$ (Fig. 3)]. Younger and older patients had similar tumor sizes (2.31 vs. 2.54 cm³) indicating that younger patient had improved facial nerve preservation despite tumor size. Furthermore older patients (>57 years old), treated with higher levels of radiation (>13 Gy) had significantly worse facial nerve outcomes than younger patient (<57 years old) treated with similarly higher radiation doses of greater than 13 Gy ($P < 0.0010$). Younger age may be an important prognostic factor for improved facial nerve preservations with GKRS for VS.




Fig. 3 Facial nerve preservation analyzed as a function of age with an age cut off of older or younger than 60 years old (*P* value indicated)

Discussion

Facial nerve preservation continues to be a primary concern of patients undergoing Gamma Knife radiosurgery for vestibular schwannomas. Despite the currently available data there have been few efforts to combine this research into accurate estimates of facial nerve preservation with GKRS for VS. In this study we performed a comprehensive analysis of facial nerve functional preservation in a large aggregated population of patients who underwent GKRS for vestibular schwannomas.

Our methodical analysis revealed that patients treated with a marginal dose of less than 13 Gy were more likely to preserve facial nerve function after GKRS treatment than studies that delivered higher doses of radiation. Higher doses of radiation are associated with higher rates of cranial nerve toxicity [67, 78–81]. One possible reason for this is the significant amount of fibrosis within and around the vestibular schwannoma, involving the adjacent cochlear and facial nerves. This finding has been noted in surgical salvage after failed irradiation [82, 83]. Several recent studies have demonstrated that low dose radiosurgery has a favorable efficacy/toxicity ratio as compared to higher doses [4, 23, 40, 44, 48, 57, 61, 84]. In our analysis patients treated with lower dose Gamma Knife radiosurgery (<13 Gy) had superior facial nerve preservation rates [<13 Gy = 98.5% vs. >13 Gy = 94.7%, $P < 0.0001$ (Fig. 1)] with good tumor control rates of 96.7% at a reported average length of follow up duration of 54.1 months (Median 43.0 months).

In our objective analysis, patients with an average tumor volume of 1.5 cm³ or less had a better facial nerve preservation rate compared to studies with tumors of larger volumes [≤ 1.5 cm³ 99.5% vs. >1.5 cm³ 95.5%, $P < 0.0001$ (Fig. 2)]. Smaller tumors had improved facial preservation rates and lower average radiation doses for smaller tumors (12.9 ± 0.8 Gy vs. 13.7 ± 1.3 Gy, $P < 0.0001$). This data suggests that both smaller tumor size and lower radiosurgery dose are important risk factors for facial nerve preservation with Gamma knife radiosurgery treatment. Although it appears that radiation dose is an important associated factor with facial nerve preservation, our data does not permit the discrimination between size or radiation dose as the more significant parameter for facial nerve preservation as both smaller tumors and lower radiation doses both had improved outcomes. Our data does not clarify this ambiguity about whether size or radiation dose has a more significant impact on facial nerve preservation.

Older patients commonly have medically related comorbidities which can preclude them from open brain surgery. Our analysis indicates that older patients with age >60 years had inferior facial nerve preservation rates than younger patients [<60 years = 96.8% vs. >60 years = 89.4%, $P < 0.0001$ (Fig. 3)]. Age may be an important

prognostic factor for facial nerve preservation despite tumor size or radiation dose. Older patients had similar tumor sizes as younger patients (2.31 vs. 2.54 cm³). Advanced age does appear to be a negative prognostic factor in facial nerve preservation outcomes in patients treated with GKRS for VS. Furthermore older patients (>57 years old), treated with high levels of radiation (>13 Gy) had significantly worse facial nerve outcomes than younger patient (<57 years old) treated with similarly high radiation doses of greater than 13 Gy ($P < 0.0010$). Our data suggests that older age may be significantly associated with worse facial nerve preservation independent of radiation dose because older patients did worse with high radiation doses than their younger counterparts who also received high radiation doses (>13 Gy).

The various methods of data presentation reported in the papers for our systematic analysis precluded us from further investigation to stratify other statistically significant data points. Unfortunately actuarial time dependant data was not possible in our retrospective, systematic analysis as this is an inherent limitation in the methodology of our study. Similarly, multi-variable analysis and a logistic regression analysis are also problematic across multiple studies which adhere to differing formats of data presentation.

Prospective studies could further elucidate the actuarial nature of facial nerve preservation over time after GKRS and may also provide further insight into the exact relationship between the prognostic variables we investigated here and facial nerve preservation. Our systematic analysis is the first reported attempt to comprehensively evaluate the overall impact of GKRS for VS on facial nerve function as described in the published literature.

There are some inherent limitations with systematic reviews and analysis [85]. One obvious limitation is that any aggregation of data is only as good as its composite studies. The quality of the data reported in the literature, the effect of failure to detect, or unwillingness to report complications, and other such omissions would inevitably change and skew the result reported in our aggregated analysis. Furthermore, small sample size reports that met our inclusion criteria were also included in our analysis. Although their contribution is small, we mitigated the effect of case reports and small samples by analyzing an aggregated database and by weighting the appropriate contribution of each paper by the number of patients with facial nerve intact before GKRS accordingly. Hence in our analysis, smaller sample sizes and case reports had a proportionate effect on our overall aggregated facial nerve preservation data. However, the large nature of our systematic review minimizes the biases and dilutes the inherent error of any individual study in our comprehensive report and also has the advantage of expansive results from multiple international centers.

In conclusion, we report the results from a large aggregated analysis of facial nerve outcomes in patients with vestibular schwannoma treated specifically with Gamma Knife radiosurgery. Utilizing this systematic data set from the available published literature, minimizes the effect of bias and dilutes the inherent error from individual institutions, increases the statistical power of our analysis, and aggregates expansive results to determine an accurate and overall facial nerve preservation for patients treated with Gamma Knife radiosurgery for vestibular schwannomas. This systematic analysis suggests that radiation dose is an important and critical prognostic factor for facial nerve outcomes in VS patients treated with GKRS. Our data also confirms that patients treated with 13 Gy or less of radiation, with tumors less than 1.5 cm³ in size, and younger patients have improved facial nerve outcomes.

Acknowledgments IY the first author was partially supported by a UCSF Clinical and Translational Scientist Training Research Award in performing this investigation. ATP senior author is partially funded by the Reza and Georgianna Khatib Endowed Chair in Skull Base Tumor Surgery.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Delbrouck C, Hassid S, Massager N, Choufani G, David P, Devriendt D, Levivier M (2003) Preservation of hearing in vestibular schwannomas treated by radiosurgery using Leksell Gamma Knife: preliminary report of a prospective Belgian clinical study. *Acta Otorhinolaryngol Belg* 57:197–204
2. Karpinos M, Teh BS, Zeck O, Carpenter LS, Phan C, Mai WY, Lu HH, Chiu JK, Butler EB, Gormley WB, Woo SY (2002) Treatment of acoustic neuroma: stereotactic radiosurgery vs. microsurgery. *Int J Radiat Oncol Biol Phys* 54:1410–1421. doi:10.1016/S0360-3016(02)03651-9
3. Kaylie DM, McMenomey SO (2003) Microsurgery vs gamma knife radiosurgery for the treatment of vestibular schwannomas. *Arch Otolaryngol Head Neck Surg* 129:903–906. doi:10.1001/archotol.129.8.903
4. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC (1998) Long-term outcomes after radiosurgery for acoustic neuromas. *N Engl J Med* 339:1426–1433. doi:10.1056/NEJM199811123392003
5. Flickinger JC, Kondziolka D, Lunsford LD (1998) Clinical applications of stereotactic radiosurgery. *Cancer Treat Res* 93:283–297
6. Noren G (1998) Long-term complications following gamma knife radiosurgery of vestibular schwannomas. *Stereotact Funct Neurosurg* 70(Suppl 1):65–73. doi:10.1159/000056408
7. Pellet W, Regis J, Roche PH, Delsanti C (2003) Relative indications for radiosurgery and microsurgery for acoustic schwannoma. *Adv Tech Stand Neurosurg* 28:227–282; discussion 282–284

8. Pogodzinski MS, Harner SG, Link MJ (2004) Patient choice in treatment of vestibular schwannoma. *Otolaryngol Head Neck Surg* 130:611–616. doi:[10.1016/j.otohns.2004.02.006](https://doi.org/10.1016/j.otohns.2004.02.006)
9. Regis J, Delsanti C, Roche P, Soumare O, Dufour H, Porcheron D, Peragut JC, Thomassin JM, Pellet W (2002) Preservation of hearing function in the radiosurgical treatment of unilateral vestibular schwannomas. Preliminary results. *Neurochirurgie* 48:471–478
10. Regis J, Pellet W, Delsanti C, Dufour H, Roche PH, Thomassin JM, Zanaret M, Peragut JC (2002) Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. *J Neurosurg* 97:1091–1100
11. Unger F, Walch C, Papaefthymiou G, Feichtinger K, Trummer M, Pendl G (2002) Radiosurgery of residual and recurrent vestibular schwannomas. *Acta Neurochir (Wien)* 144:671–676; discussion 676–677
12. Unger F, Walch C, Schrottner O, Eustacchio S, Sutter B, Pendl G (2002) Cranial nerve preservation after radiosurgery of vestibular schwannomas. *Acta Neurochir Suppl (Wien)* 84:77–83
13. Unger F, Walch C, Haselsberger K, Papaefthymiou G, Trummer M, Eustacchio S, Pendl G (1999) Radiosurgery of vestibular schwannomas: a minimally invasive alternative to microsurgery. *Acta Neurochir (Wien)* 141:1281–1285; discussion 1285–1286
14. Friedman WA, Foote KD (2003) Linear accelerator-based radiosurgery for vestibular schwannoma. *Neurosurg Focus* 14:e2
15. Shoshan Y, Wygoda M, Umansky F (2005) Stereotactic radiosurgery and fractionated stereotactic radiotherapy: background, definitions, applications. *Isr Med Assoc J* 7:597–599
16. Battista RA, Wiet RJ (2000) Stereotactic radiosurgery for acoustic neuromas: a survey of the American Neurotology Society. *Am J Otol* 21:371–381. doi:[10.1016/S0196-0709\(00\)80047-2](https://doi.org/10.1016/S0196-0709(00)80047-2)
17. Pollock BE, Lunsford LD, Kondziolka D, Flickinger JC, Bissonette DJ, Kelsey SF, Jannetta PJ (1995) Outcome analysis of acoustic neuroma management: a comparison of microsurgery and stereotactic radiosurgery. *Neurosurgery* 36:215–224; discussion 224–229
18. Sekhar LN, Gormley WB, Wright DC (1996) The best treatment for vestibular schwannoma (acoustic neuroma): microsurgery or radiosurgery? *Am J Otol* 17:676–682; discussion 683–689
19. Kameron DB, Lunsford LD, Moller M (1988) Gamma knife: an alternative treatment for acoustic neurinomas. *Ann Otol Rhinol Laryngol* 97:631–635
20. Lunsford LD, Kameron DB, Flickinger JC (1990) Stereotactic radiosurgery for acoustic neuromas. *Arch Otolaryngol Head Neck Surg* 116:907–909
21. Wiet RJ, Micco AG, Bauer GP (1996) Complications of the gamma knife. *Arch Otolaryngol Head Neck Surg* 122:414–416
22. Ramsay HA, Luxford WM (1993) Treatment of acoustic tumours in elderly patients: is surgery warranted? *J Laryngol Otol* 107:295–297. doi:[10.1017/S0022215100122868](https://doi.org/10.1017/S0022215100122868)
23. Mendenhall WM, Friedman WA, Buatti JM, Bova FJ (1996) Preliminary results of linear accelerator radiosurgery for acoustic schwannomas. *J Neurosurg* 85:1013–1019
24. Linskey ME (2000) Stereotactic radiosurgery versus stereotactic radiotherapy for patients with vestibular schwannoma: a Leksell Gamma Knife Society 2000 debate. *J Neurosurg* 93(Suppl 3):90–95
25. Yamamoto M, Hagiwara S, Ide M, Jimbo M, Hirai T, Nakamura Y (1996) Radiosurgery for acoustic neurinoma with rapid growth and relatively high staining indexes for proliferating cell nuclear antigen and MIB-1. *Neurol Med Chir (Tokyo)* 36:241–245. doi:[10.2176/nmc.36.241](https://doi.org/10.2176/nmc.36.241)
26. Flickinger JC, Lunsford LD, Linskey ME, Duma CM, Kondziolka D (1993) Gamma knife radiosurgery for acoustic tumors: multivariate analysis of four year results. *Radiother Oncol* 27:91–98. doi:[10.1016/0167-8140\(93\)90127-T](https://doi.org/10.1016/0167-8140(93)90127-T)
27. Lunsford LD, Linskey ME (1992) Stereotactic radiosurgery in the treatment of patients with acoustic tumors. *Otolaryngol Clin N Am* 25:471–491
28. Spiegelmann R, Gofman J, Alezra D, Pfeffer R (1999) Radiosurgery for acoustic neurinomas (vestibular schwannomas). *Isr Med Assoc J* 1:8–13
29. Ottaviani F, Neglia CB, Ventrella L, Giugni E, Motti E (2002) Hearing loss and changes in transient evoked otoacoustic emissions after gamma knife radiosurgery for acoustic neurinomas. *Arch Otolaryngol Head Neck Surg* 128:1308–1312
30. Ito K, Shin M, Matsuzaki M, Sugawara K, Sasaki T (2000) Risk factors for neurological complications after acoustic neurinoma radiosurgery: refinement from further experiences. *Int J Radiat Oncol Biol Phys* 48:75–80. doi:[10.1016/S0360-3016\(00\)00570-8](https://doi.org/10.1016/S0360-3016(00)00570-8)
31. Yang I, Barbaro NM (2007) Advances in the radiosurgical treatment of epilepsy. *Epilepsy Curr/Am Epilepsy Soc* 7:31–35
32. Chin LS, Lazio BE, Biggins T, Amin P (2000) Acute complications following gamma knife radiosurgery are rare. *Surg Neurol* 53:498–502; discussion 502
33. de Ipolyi AR, Yang I, Buckley A, Barbaro NM, Cheung SW, Parsa AT (2008) Fluctuating response of a cystic vestibular schwannoma to radiosurgery: case report. *Neurosurgery* 62:E1164–E1165, E:1165 discussion
34. Doherty JK, Friedman RA (2006) Controversies in building a management algorithm for vestibular schwannomas. *Curr Opin Otolaryngol Head Neck Surg* 14:305–313. doi:[10.1097/01.moo.0000244186.72645.d4](https://doi.org/10.1097/01.moo.0000244186.72645.d4)
35. Linskey ME, Lunsford LD, Flickinger JC (1990) Radiosurgery for acoustic neurinomas: early experience. *Neurosurgery* 26:736–744; discussion 744–745
36. Linskey ME, Johnstone PA, O'Leary M, Goetsch S (2003) Radiation exposure of normal temporal bone structures during stereotactically guided gamma knife surgery for vestibular schwannomas. *J Neurosurg* 98:800–806
37. Smith MC, Ryken TC, Buatti JM (2006) Radiotoxicity after conformal radiation therapy for benign intracranial tumors. *Neurosurg Clin N Am* 17:169–180. doi:[10.1016/j.nec.2006.04.002](https://doi.org/10.1016/j.nec.2006.04.002)
38. Mendenhall WM, Friedman WA, Bova FJ (1994) Linear accelerator-based stereotactic radiosurgery for acoustic schwannomas. *Int J Radiat Oncol Biol Phys* 28:803–810
39. Spiegelmann R, Lidar Z, Gofman J, Alezra D, Hadani M, Pfeffer R (2001) Linear accelerator radiosurgery for vestibular schwannoma. *J Neurosurg* 94:7–13
40. Foote KD, Friedman WA, Buatti JM, Meeks SL, Bova FJ, Kubilis PS (2001) Analysis of risk factors associated with radiosurgery for vestibular schwannoma. *J Neurosurg* 95:440–449
41. Myrseth E, Moller P, Pedersen PH, Vassbotn FS, Wentzel-Larsen T, Lund-Johansen M (2005) Vestibular schwannomas: clinical results and quality of life after microsurgery or gamma knife radiosurgery. *Neurosurgery* 56: 927–935; discussion 927–935
42. Shin YJ, Lapeyre-Mestre M, Gafsi I, Cognard C, Deguine O, Tremoulet M, Fraysse B (2003) Neurological complications after radiosurgery versus conservative management in acoustic neuromas: a systematic review-based study. *Acta Otolaryngol* 123:59–64. doi:[10.1081/0036554021000028084](https://doi.org/10.1081/0036554021000028084)
43. Chung WY, Liu KD, Shiao CY, Wu HM, Wang LW, Guo WY, Ho DM, Pan DH (2005) Gamma knife surgery for vestibular schwannoma: 10-year experience of 195 cases. *J Neurosurg* 102(Suppl):87–96
44. Andrews DW, Suarez O, Goldman HW, Downes MB, Bednarz G, Corn BW, Werner-Wasik M, Rosenstock J, Curran WJ Jr (2001) Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution. *Int J Radiat Oncol Biol Phys* 50:1265–1278. doi:[10.1016/S0360-3016\(01\)01559-0](https://doi.org/10.1016/S0360-3016(01)01559-0)

45. Meijer OW, Vandertop WP, Baayen JC, Slotman BJ (2003) Single-fraction vs. fractionated linac-based stereotactic radiosurgery for vestibular schwannoma: a single-institution study. *Int J Radiat Oncol Biol Phys* 56:1390–1396. doi:[10.1016/S0360-3016\(03\)00444-9](https://doi.org/10.1016/S0360-3016(03)00444-9)
46. Meijer OW, Wolbers JG, Baayen JC, Slotman BJ (2000) Fractionated stereotactic radiation therapy and single high-dose radiosurgery for acoustic neuroma: early results of a prospective clinical study. *Int J Radiat Oncol Biol Phys* 46:45–49. doi:[10.1016/S0360-3016\(99\)00363-6](https://doi.org/10.1016/S0360-3016(99)00363-6)
47. Thomsen J, Tos M, Borgesen SE (1990) Gamma knife: hydrocephalus as a complication of stereotactic radiosurgical treatment of an acoustic neuroma. *Am J Otol* 11:330–333
48. Kondziolka D, Subach BR, Lunsford LD, Bissonette DJ, Flickinger JC (1998) Outcomes after gamma knife radiosurgery in solitary acoustic tumors and neurofibromatosis type 2. *Neurosurg Focus* 5:e2. doi:[10.3171/foc.1998.5.3.5](https://doi.org/10.3171/foc.1998.5.3.5)
49. Hudgins WR (1994) Patients' attitude about outcomes and the role of gamma knife radiosurgery in the treatment of vestibular schwannomas. *Neurosurgery* 34:459–463; discussion 463–465
50. House JW, Brackmann DE (1985) Facial nerve grading system. *Otolaryngol Head Neck Surg* 93:146–147
51. Silverstein H, Willcox TO Jr, Rosenberg SI, Seidman MD (1994) Prediction of facial nerve function following acoustic neuroma resection using intraoperative facial nerve stimulation. *Laryngoscope* 104:539–544. doi:[10.1288/00005537-199412000-00002](https://doi.org/10.1288/00005537-199412000-00002)
52. Ross BG, Fradet G, Nedzelski JM (1996) Development of a sensitive clinical facial grading system. *Otolaryngol Head Neck Surg* 114:380–386. doi:[10.1016/S0194-5998\(96\)70206-1](https://doi.org/10.1016/S0194-5998(96)70206-1)
53. Neely JG, Joaquin AH, Kohn LA, Cheung JY (1996) Quantitative assessment of the variation within grades of facial paralysis. *Laryngoscope* 106:438–442. doi:[10.1097/00005537-199604000-00009](https://doi.org/10.1097/00005537-199604000-00009)
54. Rickenmann J, Jaquenod C, Cerenko D, Fisch U (1997) Comparative value of facial nerve grading systems. *Otolaryngol Head Neck Surg* 117:322–325. doi:[10.1016/S0194-5998\(97\)70120-7](https://doi.org/10.1016/S0194-5998(97)70120-7)
55. Chopra R, Kondziolka D, Niranjan A, Lunsford LD, Flickinger JC (2007) Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. *Int J Radiat Oncol Biol Phys* 68:845–851. doi:[10.1016/j.ijrobp.2007.01.001](https://doi.org/10.1016/j.ijrobp.2007.01.001)
56. Hempel JM, Hempel E, Wowra B, Schichor C, Muacevic A, Riederer A (2006) Functional outcome after gamma knife treatment in vestibular schwannoma. *Eur Arch Otorhinolaryngol* 263:714–718. doi:[10.1007/s00405-006-0054-6](https://doi.org/10.1007/s00405-006-0054-6)
57. Hasegawa T, Kida Y, Kobayashi T, Yoshimoto M, Mori Y, Yoshida J (2005) Long-term outcomes in patients with vestibular schwannomas treated using gamma knife surgery: 10-year follow up. *J Neurosurg* 102:10–16
58. Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D (2005) Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. *J Neurosurg* 102(Suppl):195–199
59. Inoue HK (2005) Low-dose radiosurgery for large vestibular schwannomas: long-term results of functional preservation. *J Neurosurg* 102(Suppl):111–113
60. Wackym PA, Runge-Samuelson CL, Poetker DM, Michel MA, Alkaf FM, Burg LS, Firszt JB (2004) Gamma knife radiosurgery for acoustic neuromas performed by a neurotologist: early experiences and outcomes. *Otol Neurotol* 25:752–761. doi:[10.1097/00129492-200409000-00018](https://doi.org/10.1097/00129492-200409000-00018)
61. Flickinger JC, Kondziolka D, Niranjan A, Maitz A, Vovnov G, Lunsford LD (2004) Acoustic neuroma radiosurgery with marginal tumor doses of 12 to 13 Gy. *Int J Radiat Oncol Biol Phys* 60:225–230. doi:[10.1016/j.ijrobp.2004.02.019](https://doi.org/10.1016/j.ijrobp.2004.02.019)
62. Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA (2003) Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. *J Neurol Neurosurg Psychiatry* 74:1288–1293. doi:[10.1136/jnnp.74.9.1288](https://doi.org/10.1136/jnnp.74.9.1288)
63. Watanabe T, Saito N, Hirato J, Shimaguchi H, Fujimaki H, Sasaki T (2003) Facial neuropathy due to axonal degeneration and microvasculitis following gamma knife surgery for vestibular schwannoma: a histological analysis. Case report. *J Neurosurg* 99:916–920
64. Kondziolka D, Nathoo N, Flickinger JC, Niranjan A, Maitz AH, Lunsford LD (2003) Long-term results after radiosurgery for benign intracranial tumors. *Neurosurgery* 53:815–821; discussion 821–822
65. Moffat DA, Quaranta N, Baguley DM, Hardy DG, Chang P (2003) Management strategies in neurofibromatosis type 2. *Eur Arch Otorhinolaryngol* 260:12–18
66. Kura M, Terahara A, Nakagawa K, Aoki Y, Ohtomo K, Shin M, Kurita H (2000) Immediate neurological deterioration after gamma knife radiosurgery for acoustic neuroma. Case report. *J Neurosurg* 93(Suppl 3):78–81
67. Niranjan A, Lunsford LD, Flickinger JC, Maitz A, Kondziolka D (1999) Dose reduction improves hearing preservation rates after intracanalicular acoustic tumor radiosurgery. *Neurosurgery* 45:753–762; discussion 762–765
68. Subach BR, Kondziolka D, Lunsford LD, Bissonette DJ, Flickinger JC, Maitz AH (1999) Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis type 2. *J Neurosurg* 90:815–822
69. Miller RC, Foote RL, Coffey RJ, Sargent DJ, Gorman DA, Schomberg PJ, Kline RW (1999) Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume. *Int J Radiat Oncol Biol Phys* 43:305–311. doi:[10.1016/S0360-3016\(98\)00397-6](https://doi.org/10.1016/S0360-3016(98)00397-6)
70. Pollock BE, Lunsford LD, Flickinger JC, Clyde BL, Kondziolka D (1998) Vestibular schwannoma management. Part I. Failed microsurgery and the role of delayed stereotactic radiosurgery. *J Neurosurg* 89:944–948
71. Ito K, Kurita H, Sugawara K, Mizuno M, Sasaki T (1997) Analyses of neuro-otological complications after radiosurgery for acoustic neurinomas. *Int J Radiat Oncol Biol Phys* 39:983–988. doi:[10.1016/S0360-3016\(97\)00507-5](https://doi.org/10.1016/S0360-3016(97)00507-5)
72. Flickinger JC, Kondziolka D, Lunsford LD (1996) Dose and diameter relationships for facial, trigeminal, and acoustic neuropathies following acoustic neuroma radiosurgery. *Radiother Oncol* 41:215–219. doi:[10.1016/S0167-8140\(96\)01831-2](https://doi.org/10.1016/S0167-8140(96)01831-2)
73. Flickinger JC, Kondziolka D, Pollock BE, Lunsford LD (1996) Evolution in technique for vestibular schwannoma radiosurgery and effect on outcome. *Int J Radiat Oncol Biol Phys* 36:275–280. doi:[10.1016/S0360-3016\(96\)00335-5](https://doi.org/10.1016/S0360-3016(96)00335-5)
74. Slattery WH III, Brackmann DE (1995) Results of surgery following stereotactic irradiation for acoustic neuromas. *Am J Otol* 16:315–319; discussion 319–321
75. Ogunrinde OK, Lunsford LD, Flickinger JC, Kondziolka DS (1995) Cranial nerve preservation after stereotactic radiosurgery for small acoustic tumors. *Arch Neurol* 52:73–79
76. Ogunrinde OK, Lunsford DL, Kondziolka DS, Bissonette DJ, Flickinger JC (1995) Cranial nerve preservation after stereotactic radiosurgery of intracanalicular acoustic tumors. *Stereotact Funct Neurosurg* 64(Suppl 1):87–97
77. Linskey ME, Lunsford LD, Flickinger JC (1992) Tumor control after stereotactic radiosurgery in neurofibromatosis patients with bilateral acoustic tumors. *Neurosurgery* 31:838–839; discussion 838–839
78. Hirato M, Inoue H, Zama A, Ohye C, Shibasaki T, Andou Y (1996) Gamma knife radiosurgery for acoustic schwannoma: effects of low radiation dose and functional prognosis. *Stereotact Funct Neurosurg* 66(Suppl 1):134–141. doi:[10.1159/00099803](https://doi.org/10.1159/00099803)

79. Niranjan A, Lunsford LD, Flickinger JC, Maitz A, Kondziolka D (1999) Can hearing improve after acoustic tumor radiosurgery? *Neurosurg Clin N Am* 10:305–315
80. Petit JH, Hudes RS, Chen TT, Eisenberg HM, Simard JM, Chin LS (2001) Reduced-dose radiosurgery for vestibular schwannomas. *Neurosurgery* 49:1299–1306; discussion 1306–1307
81. Rutten I, Baumert BG, Seidel L, Kotolenko S, Collignon J, Kaschten B, Albert A, Martin D, Deneufbourg JM, Demanez JP, Stevenaert A (2007) Long-term follow-up reveals low toxicity of radiosurgery for vestibular schwannoma. *Radiother Oncol* 82:83–89. doi:[10.1016/j.radonc.2006.11.019](https://doi.org/10.1016/j.radonc.2006.11.019)
82. Friedman RA, Brackmann DE, Hitselberger WE, Schwartz MS, Iqbal Z, Berliner KI (2005) Surgical salvage after failed irradiation for vestibular schwannoma. *Laryngoscope* 115:1827–1832. doi:[10.1097/01.mlg.0000175063.76945.75](https://doi.org/10.1097/01.mlg.0000175063.76945.75)
83. Limb CJ, Long DM, Niparko JK (2005) Acoustic neuromas after failed radiation therapy: challenges of surgical salvage. *Laryngoscope* 115:93–98
84. Hasegawa T, Fujitani S, Katsumata S, Kida Y, Yoshimoto M, Koike J (2005) Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years. *Neurosurgery* 57:257–265; discussion 257–265
85. Barker FGII, Carter BS (2005) Synthesizing medical evidence: systematic reviews and metaanalyses. *Neurosurg Focus* 19:E5. doi:[10.3171/foc.2005.19.4.6](https://doi.org/10.3171/foc.2005.19.4.6)